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OBJECTIVES: DRAKO (NCT02850263) is a 24-month, prospective, non-interventional, multi-centre cohort study which enroled
patients diagnosed with centre-involving diabetic macular oedema (DMO). The study aims to evaluate standard of care with
intravitreal aflibercept (IVT-AFL) treatment in the UK. This analysis describes the anti-vascular endothelial growth factor (anti-VEGF)
treatment-naive patient cohort after 12-month follow-up.
METHODS: Study eyes were treated with IVT-AFL as per local standard of care. The mean change in best-corrected visual acuity
(BCVA) and central subfield thickness (CST) from baseline at 12 months were measured and stratified by baseline factors. The
number of injections and safety data were also evaluated.
RESULTS: A total of 507 patients were enroled from 35 centres. Mean (SD) baseline BCVA was 71.4 (12.0) letters and CST was 448.7
(88.7) µm, with 63.1% of patients presenting with baseline BCVA ≥ 70 letters (mean 78.1). Mean (SD) change in BCVA of 2.5 (12.2)
letters and CST of −119.1 (116.4) µm was observed at month 12. A 7.3 letter gain was observed in patients with baseline BCVA < 70
letters. Mean number (SD) of injections in year one was 6.4 (2.1). No significant adverse events were recorded.
CONCLUSION: Year one results indicated that IVT-AFL was an effective treatment for DMO in standard of care UK clinical practice,
maintaining or improving visual acuity in treatment-naive patients with good baseline visual acuity, despite some patients being
undertreated versus the summary of product characteristics. These results also demonstrated the clinical importance and
meaningful impact of diabetic retinopathy screening in the UK.
Eye; https://doi.org/10.1038/s41433-021-01624-9
INTRODUCTION
Diabetes, including its associated complications, is an escalating
healthcare problem, with treatment estimated to cost around 10%
of the UK’s entire National Health Service (NHS) budget [1]. The
global prevalence of diabetes is projected to increase from the
current 9.3% to 10.2% in 2030, affecting 578.4 million adults
between the ages of 20–79 years, further increasing the burden on
health systems [2]. Diabetic macular oedema (DMO), a micro-
vascular complication of diabetes that can occur at any stage of
retinopathy, is the most common cause of visual acuity (VA) loss in
patients with diabetes and the most frequent cause of
blindness in young and mid-aged adults in the developed world.
One in four diabetic patients can expect to develop DMO in their
lifetime [3–6].
In recent years, the use of anti-vascular endothelial growth
factor (anti-VEGF) treatments for DMO has seen outcomes for
many patients improve. Intravitreal injections of anti-VEGF
therapies have shown superiority over laser photocoagulation of
the macula in several clinical trials [7–10]. Subsequently,
intravitreal VEGF inhibitors have become the first-line therapy of
choice for management of vision loss from DMO.
Intravitreal aflibercept (IVT-AFL, Eylea) is an anti-VEGF treatment
with an innovative fusion protein design. Current IVT-AFL standard
of care treatment for DMO patients is a 2 mg dose of five initial
monthly injections followed by a proactive bi-monthly treatment
regimen in year one, with no requirement for monitoring between
injections. In year two, the injection interval may be extended
dependent on functional and anatomical outcomes, consequently
reducing burden on patients and their care providers (IVT-AFL
summary of product characteristics [SmPC] recommended posol-
ogy for DMO treatment) [11].
Results from the two pivotal IVT-AFL Phase 3 trials in DMO,
VIVIDDMO and VISTADMO, demonstrated significant superiority for
the IVT-AFL treatment groups over laser in all endpoints at week
52 through to week 148, with similar efficacy in both treatment
regimens [10, 12, 13].
The UK did not participate in these pivotal trials, and DRAKO
represents the first UK-based prospective, non-interventional
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study to assess the effectiveness of standard of care IVT-AFL
treatment in DMO patients. Such observational studies are
valuable as they report and evaluate outcomes based on locally
defined treatment practices, outside the rigorous clinical trial
setting, enabling outcome characterisation within a more
representative population and treatment environment.
The primary objectives of this study are to assess the mean
change from baseline in best-corrected visual acuity (BCVA) and
central subfield thickness (CST). In addition, by evaluating follow-
up procedures and assessing treatment patterns in eyes affected
by DMO treated with IVT-AFL in routine clinical practice, the study
aims to inform best practice guidance in the UK upon completion
of the follow-up period. Here we describe the month 12 outcomes
of the anti-VEGF treatment-naive patient cohort.
MATERIALS AND METHODS
Study design
DRAKO (NCT02850263) is a prospective, non-interventional, multi-centre,
non-comparative cohort study conducted in 35 NHS hospitals through-
out the UK (Supplementary Table 1). Patients were enroled from July
2016 through to April 2018 and followed up for 24 months. To reduce
selection bias, patients were enroled in a consecutive manner. The study
was approved by the North West Liverpool East Research Ethics
Committee (16/NW/0238) and was conducted in accordance with the
Declaration of Helsinki. All participants provided written informed
consent. All treatment decisions, including the decision to treat with
IVT-AFL, were made as per local standard of care, independently of study
participation. The study included two patient cohorts; Cohort 1
comprised anti-VEGF treatment-naive patients and Cohort 2 comprised
patients who previously received anti-VEGF treatment other than IVT-
AFL for DMO. Study size was calculated based on an assumed 10% drop-
out rate at 24 months, allowing an estimate of change from baseline in
BCVA letters within 95% confidence intervals (CI) of ±1.2 letters and CST
of ±13.9 μm. This was based on a standard deviation (SD) of 13 letters for
the mean change in BCVA and 150 µm for CST, conservative estimates
based on SD observed in other recent studies involving aflibercept in
DMO [10, 14]. Sample sizes of 450 and 225 were calculated for Cohorts 1
and 2 respectively.
Study population and treatment
Adult patients with a confirmed diagnosis of type 1 or type 2 diabetes and
DMO with central involvement, defined as the centre subfield area on optical
coherence tomography, were enroled if they met the eligibility criteria as
defined in Table 1. Inclusion of patients based on a CST of ≥400 µm in the
study eye was removed as an eligibility criterion via protocol amendment (21
February 2017) as this threshold is not applied in Scotland and removal
enabled a more accurate representation of the UK-treated population. One of
the two participating Scottish sites (University Hospital Hairmyres) was active
prior to approval of the protocol amendment. The study eye was defined as
the eye for which the IVT-AFL treatment was initiated or, if both eyes were
affected, the eye with worse baseline VA. Data were collected for the fellow
eye if DMO diagnosis was confirmed. No eligibility restriction was mandated
for patient baseline BCVA letter score.
At study initiation, details of the local standard of care IVT-AFL treatment
protocol was recorded for each centre (Supplementary Table 2). Data
collection, including type of visit; diabetic management (diabetic retino-
pathy measured using the English National Screening Committee or
Scottish Diabetic Retinopathy Grading Scheme classifications, and
haemoglobin A1c (HbA1c) assessment), anatomical and functional assess-
ments; treatment provided from the baseline visit; and all subsequent
routine outpatient visits were recorded. The month 12 visit was nominated
by the site (for data collection purposes) and defined as 12 months ±1
month from the patient’s baseline visit.
Patients who dropped out of the study for any reason were not replaced.
Outcome measures
Primary outcomes were the mean change from baseline in Early Treatment
Diabetic Retinopathy Study (ETDRS) letters measured by BCVA with refraction
and the mean change in CST as determined by spectral domain optical
coherence tomography (as per local practice) at month 12. Secondary
objectives included mean change in BCVA and CST stratified by pre-defined
baseline factors; percentage gain and loss of at least 5, 10 or 15 letters; and
adherence to IVT-AFL DMO SmPC in year one. Due to the observational
design of the study, target changes in these parameters were not defined.
Table 1. Patient inclusion and exclusion criteria based on cohort for the DRAKO non-interventional study.
Inclusion criteria
Universal study inclusion criteria Anti-VEGF treatment-naive cohort specific criteria
Aged 18 years or older Not previously received anti-VEGF treatment
Type 1 or 2 diabetes mellitus diagnosis Not received pan-retinal photocoagulation treatment in the past 8 weeks
Not received macular laser photocoagulation treatment in the past
4 months
DMO diagnosis with central involvement Not previously received intravitreal dexamethasone steroid or fluocinolone
acetonide treatment
Prior Anti-VEGF treatment other than IVT-AFL cohort specific criteria
Decision to initiate IVT-AFL treatment made as per routine practice
and before study inclusion
Previously treated with an intravitreal anti-VEGF other than aflibercept
for DMO
Not received intravitreal anti-VEGF treatment in the past 28 days
Written informed consent Not received intravitreal dexamethasone steroid treatment in the past
6 months
Exclusion criteria
Contraindications as listed in the SmPC for IVT-AFL
Pre-planned cataract surgery during the observational period
Currently or previously treated with systemic anti-VEGF
Previously treated with intravitreal fluocinolone acetonide steroid
Participating in an investigational programme with interventions outside of routine clinical practice
Women who are currently pregnant or lactating and/or planning pregnancy within the next 2 years
Known hypersensitivity to any excipients
Active or suspected ocular/periocular infection or periocular inflammation
DMO diabetic macular oedema, IVT-AFL intravitreal aflibercept, anti-VEGF anti-vascular endothelial growth factor, SmPC summary of product characteristics.
















Interim analysis was conducted upon completion of the 12-month follow-
up period for the treatment-naive patient cohort and are reported here.
Descriptive statistics were used to summarise the quantitative variables.
Categorical variables were summarised using frequency distributions and
percentages and data stratified by pre-defined baseline covariate
subgroups; age (18–35, 36–50, 51–65, >65 years), BCVA (<35, 35–49,
50–69, ≥70 letters) and CST (<400, ≥400 µm).
All patients with a baseline IVT-AFL injection and at least one post-
baseline assessment of BCVA or CST were included in the analysis. Two
sub-populations were analysed, and 95% CI were calculated. The more
stringent sub-population, defined as the per protocol window population
(PPW), included patients with available BCVA or CST data at baseline and
the nominated month 12 visit (12 months ± 1 month). The less stringent
sub-population was defined as the full analysis set (FAS) and included
patients with BCVA or CST available at baseline and at least one follow-up
visit; missing values were imputed based on the last observation carried
forward method, the visit immediately preceding the month 12 visit was
used for analysis. Adherence to SmPC was measured by defining
acceptable ‘windows’ between injections. For the first five injections, it
was 25–38 days; after the fifth injection, it was 46–66 days.
Safety was assessed on the safety set, which included all patients who
provided written informed consent. Adverse events were listed using the
Medical Dictionary for Regulatory Activities coding system.
Analysis was performed using SAS® software, version 9.4 (SAS Institute
Inc., Cary, NC, USA).
RESULTS
Patient disposition and baseline characteristics
DRAKO enroled 507 anti-VEGF treatment-naive patients. A 2.0% drop-
out rate was observed in year one, the reasons for drop-out were as
follows; patient withdrawal (4), death (3), patient ineligibility (2) and
change in centre (1). Further patients were excluded from the analysis
due to unavailability of baseline and/or 12-month data. Patients were
507 anti-VEGF treatment-naïve DMO 
patients enrolled in DRAKO
505 patients eligible for analysis and 
two analysis sub-populations were 
defined
2 patients excluded due to ineligibilitySafety population, n=507
Reason for exclusion from PPW, n=100
• BCVA or CST data not available for 
Baseline or Month 12 visit within 
window n=100
Reason for exclusion from FAS, n=17
• BCVA and CST data not available n=9
• Patient withdrawal n=4
• Death n=3
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BCVA subgroups:
• <35 letters,  n=7
• 35–49 letters, n=12 
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BCVA subgroups:
• <35 letters,  n=11
• 35–49 letters, n=18 
• 50–69 letters, n=143
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Fig. 1 Patient disposition during the study and analysis summary. DMO diabetic macular oedema, anti-VEGF anti-vascular endothelial
growth factor, IVT-AFL intravitreal aflibercept, PPW per protocol window population, FAS full analysis set, BCVA best-corrected visual acuity,
CST central subfield thickness, n number of patients per group.
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divided into PPW (n= 388) and FAS (n= 488) sub-populations for
analysis based on pre-defined stringency criteria (Fig. 1). The PPW and
FAS sub-populations demonstrated comparable trends throughout
the analysis and results for the PPW sub-population are reported
unless stated otherwise.
The mean age at baseline was 62.9 years, and 63.1% of patients
were male (Table 2). Most patients were white (76.8%), and 85.8%
had been diagnosed with type 2 diabetes. Over half of patients
had fellow eye involvement. Patients demonstrated a suboptimal
level of glycaemic control with mean (SD) HbA1c of 66.1 (20.5)
mmol/mol. Background to pre-proliferative retinopathy was
recorded for the majority of patients regardless of classification
applied. On average, patients had been diagnosed with DMO 1.3
(SD 2.4) years before their baseline visit. Of the primary endpoint
assessments, BCVA was recorded for 91.0% of patients and CST for
99.5% of patients. The mean (SD) baseline BCVA and CST were
71.4 (12.0) letters and 448.7 (88.7) µm, respectively (Table 3).
Treatment of DMO
Local standard of care IVT-AFL treatment was administered across
all sites, with 11 different treatment posologies recorded at study
initiation (Supplementary Table 2). All patients received at least
one IVT-AFL injection in the study eye. The mean number (SD) of
injections was 6.4 (2.1) and 6.3 (2.2) for the PPW and FAS sub-
populations, respectively, compared with eight to nine injections if
treatment was conducted as per the SmPC. At site initiation, 27
(77.1%) and 21 (60.0%) of the 35 participating sites confirmed
their intention to adhere to DMO SmPC for the five initial monthly
injections and for 12 months respectively as per their local
standard of care protocol. This equated to 334 patients (86.1%)
from the 27 sites intending to administer five initial injections and
211 (54.4%) from the 21 sites intending to adhere to SmPC
throughout year one. However, in practice, 117 (30.2%) of patients
received five initial IVT-AFL injections and 13 (3.4%) patients
adhered to SmPC in year one.
Effect of treatment on functional and anatomical outcomes
The mean (95% CI) improvement in BCVA at month 12 was 2.5
letters (±1.3 letters) and 1.9 letters (±1.0 letters) for the PPW and
FAS sub-populations, respectively (Table 3). The relative increase
in BCVA letters varied based on initial VA. Patients with baseline
BCVA of less than 35 letters benefitted from a mean increase of
23.6 letters (n= 7), whereas the mean BCVA for patients
presenting with BCVA of 70 letters or more remained stable
(Fig. 2A and Supplementary Table 3). Similarly, patients aged
18–35 years experienced a larger increase in mean BCVA letters
than those aged 65 years and older (4.3 and 1.2 letters,
respectively; Supplementary Table 3). A letter gain of five or more
was observed in 40.2% of patients, whereas an equivalent letter
loss was noted in 16.5% patients (Fig. 2B). When evaluated by
adherence to SmPC, patients receiving five initial monthly
injections obtained a mean (SD) letter gain of 4.2 (10.9). The
small proportion of patients for whom treatment continued as per
SmPC in year one experienced a 1.1 (7.4) letter gain (Supplemen-
tary Table 4).
At month 12, CST was reduced, with mean (95% CI) change
from baseline determined as –119.1 µm (±11.6 µm) and –117.7 µm
(±10.1 µm) for the PPW and FAS sub-populations, respectively
(Table 3). Baseline CST was <400 µm for 16.5% of patients. Mean
(SD) CST change was observed as –42.5 (76.3) µm and –134.3
(117.0) µm for patients with initial CST measure of <400 µm and
≥400 µm, respectively (Fig. 2C and Supplementary Table 5). A
larger improvement in BCVA was observed at month 12 for
patients presenting with a baseline CST of ≥400 µm (mean [SD]
BCVA letter change was 1.4 [9.2] and 2.7 [12.6] for patients with
CST of <400 µm and ≥400 µm, respectively; see Supplementary
Table 3).
Adverse events
The safety set comprised data from the full treatment-naive
patient cohort (n= 507). During the first 12 months of treatment,
a total of 3129 injections were administered to the study eye. Non-
ocular treatment emergent adverse events (TEAE) were reported
for 33.7% (n= 171) of patients and ocular TEAEs for 13.2% (n= 67)
of patients. A total of 107 ocular TEAEs were captured. Reported
TEAEs (percentage of patients) included vitreous haemorrhage
(3.0%), cataract (1.2%), retinal haemorrhage (1.2%), retinal
Table 2. Patient demographics and baseline characteristics per sub-
population.
PPW FAS
Age, years, mean (SD)
All 62.9 (11.6) 62.4 (11.6)
18–35 30 (4.3) 29.4 (4.4)
36–50 45.2 (3.5) 45.6 (3.4)
51–65 58.9 (4.3) 58.7 (4.2)
>65 73.4 (5.9) 73.3 (5.8)
Sex, n (%)
Male 245 (63.1) 303 (62.1)
Female 143 (36.9) 185 (37.9)
Race or ethnicity, n (%)
White 298 (76.8) 374 (76.6)
Asian 38 (9.8) 50 (10.2)
Black 29 (7.5) 38 (7.8)
Mixed 4 (1.0) 4 (0.8)
Hispanic 2 (0.5) 3 (0.6)
Unknown 14 (3.6) 15 (3.1)
Other 3 (0.8) 4 (0.8)
Diabetes type, n (%)
1 55 (14.2) 67 (13.7)
2 333 (85.8) 421 (86.3)
Diabetic retinopathy, n (%)
English Scale 265 (85.8) 340 (87.4)
R0 4 (1.5) 5 (1.5)
R1 111 (41.9) 142 (41.8)
R2 104 (39.2) 133 (39.1)
R3 46 (17.4) 60 (17.6)
Scottish Scale 44 (14.2) 49 (12.6)
R0 0 0
R1 21 (47.7) 25 (51.0)
R2 21 (47.7) 21 (42.9)
R3 2 (4.5) 3 (6.1)
R4 0 0
HbA1c (mmol/ mol), n mean (SD)
n 194 239
Mean (SD) 66.1 (20.5) 66.2 (20.3)
Fellow eye involvement, n (%)
DMO confirmed in fellow eye 209 (53.9) 265 (54.3)
Diabetes diagnosis to baseline, mean
(SD) years
16.0 (10.5) 15.8 (10.3)
DMO diagnosis to baseline, years,
mean (SD)
1.3 (2.4) 1.3 (2.4)
SD standard deviation, n number of patients, PPW per protocol window
population, FAS full analysis set, DMO diabetic macular oedema.
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detachment (0.2%) and vitreous detachment (0.2%). Adverse
events reported as associated with treatment were primarily
related to the procedure rather than aflibercept. The safety profile
was in line with other published studies, and no new safety
concerns were identified. Further details on reported TEAEs are
outlined in Supplementary Table 6.
DISCUSSION
DRAKO is the first prospective, multi-centre study evaluating
standard of care IVT-AFL treatment for DMO in the UK. The study
enroled 507 treatment-naive patients across 35 contributing
centres and it was noted that the majority of patients with DMO
are diagnosed and treated at a high level of VA, demonstrating
the effectiveness of the diabetic retinopathy screening pro-
gramme in the UK.
The mean baseline BCVA for DRAKO (71.4 letters) was
substantially higher than measures reported in pivotal clinical
trials (VIVIDDMO and VISTADMO aflibercept cohorts reported mean
baseline BCVA of 59.8 letters and 59.1 letters, respectively) and in
other prospective observational DMO studies (APOLLON and
POLARIS) [10, 15, 16]. Of note, two-thirds of DRAKO patients had
baseline BCVA of 70 letters or more (mean 78.1). APOLLON, a
French IVT-AFL treatment-based study enroled 77 patients
between September 2016 and July 2019, reported mean baseline
VA 62.7 letters in the treatment-naive cohort [15]. However,
eligibility was limited to patients with baseline VA ≤20/40 (≤70
ETDRS letters). POLARIS, a European-based, ranibizumab study
that recruited 125 patients within the UK cohort from September
2012 to January 2015 reported a mean baseline VA of 60.3 letters
[16]. When comparing baseline VA in these UK cohorts, a clinically
relevant difference of 11 letters in baseline VA was observed
between DRAKO and POLARIS. Although these letter changes are
not directly comparable given that DRAKO captured BCVA with
refraction and POLARIS documented non-refracted VA, these
measures are nonetheless highly correlated. This may be a further
indication of a shift towards earlier screening and treatment of
DMO within the NHS in more recent years, particularly as DRAKO
observed a mean time from diagnosis of DMO to baseline
treatment of 1.3 years, suggesting that patients are often being
diagnosed with DMO in advance of the condition being
considered clinically significant. Indeed, these results suggest that
the National Institute for Health and Care Excellence (NICE)
Technical Appraisal Guidance on the threshold for treatment
initiation (central retinal thickness of at least 400 µm) may be
encouraging early intervention to maintain or improve patient VA
in areas of the UK where these guidelines apply (England, Wales
and Northern Ireland).
DRAKO patients experienced a mean gain of 2.5 letters and a
mean reduction in CST of 119.1 µm at month 12. Trends in letter
gains and losses demonstrated that 40.2% and 20.1% patients
observed at least a 5- or 10-letter gain respectively within the first
year. Whereas, 16.5% and 9.8% patients observed at least a 5- or
10-letter loss respectively within the same period. A 5-letter gain
in the context of the high observed baseline BCVA scores may be
clinically relevant in most patients. In addition, stratification by
baseline BCVA demonstrated that better gains were achieved in
those with worse baseline BCVA. Of note, for patients with a
baseline BCVA ≤ 69 letters (mean 58.7 letters), the mean gain at
month 12 was 7.3 letters.
Although these trends reflect those seen in both IVT-AFL
treatment randomised clinical trials (VIVIDDMO and VISTADMO) and
the APOLLON observational study, the overall 12-month BCVA
letter gains observed in these studies are higher than in DRAKO
(gain of 10.7, 10.7 and 7.8 letters, respectively) [10, 15]. This
variation is likely due to the protocol-driven higher injection
numbers, particularly in the pivotal trials (patients received five
initial monthly doses followed by IVT-AFL treatment every 8 weeks)
and the increased opportunity for larger BCVA gains from a lower
baseline as a result of implementing a maximum BCVA inclusion
criteria which was not mandated for DRAKO.
Previous reports have highlighted the positive association of
injection frequency and functional outcomes for patients, with an
emphasis on the initial injections [17]. The DRAKO study authors
also advocate the administration of full initial dosing, with the
subgroup of patients receiving five initial monthly injections
obtaining a mean letter gain of 4.2, although this benefit was not
extended to year one SmPC compliance, potentially due to the
low patient numbers or high baseline BCVA. The reasons for the
lower than intended number of injections administered were not
collected and changes in standard of care treatment protocols at
participating sites were not re-assessed after site initiation.
Consequently, it was not possible to determine whether this
was due primarily to capacity constraints within the NHS or other
factors, such as clinical prioritisation, patient influences or perhaps
a more relaxed treatment approach in response to favourable
baseline metrics. Of note, APOLLON results showed a higher rate
of patients receiving five initial doses of IVT-AFL (51.9%) than
DRAKO, which may also have contributed to the higher letter gain
reported.
Overall, DRAKO patients with a baseline BCVA of ≥70 letters
maintained their vision. Those with baseline BCVA of 70–78 letters
(n= 139) gained 1.3 letters, and those with baseline BCVA > 78
(n= 94) experienced a loss of 1.8 letters. This distinction may be
important in efforts to preserve ‘driving vision’, which is
categorised in the UK as a BCVA of 70 letters or more in the
Table 3. Mean change from baseline in functional and anatomical endpoints at month 12.
Assessment Per protocol window (n= 388) Full analysis set (n= 488)
Mean (SD) 95% CI Patient number Mean (SD) 95% CI Patient number
BCVA
Baseline 71.4 (12.0) NA 375 70.8 (12.7) NA 469
Month 12 73.6 (13.9) NA 362 72.5 (14.3) NA 481
Change from baseline 2.5 (12.2) 1.3, 3.8 353 1.9 (11.3) 0.9, 2.9 469
CST
Baseline 448.7 (88.7) NA 388 452.1 (87.2) NA 488
Month 12 329.8 (92.3) NA 386 334.4 (94.1) NA 488
Change from baseline –119.1 (116.4) –130.7, –107.4 386 –117.7 (113.7) –127.8, –107.6 488
Baseline and Month 12 mean (SD) for the primary endpoints with patient number defined per analysis sub-population. Mean change in BCVA and CST from
Baseline were reported, and 95% CI were calculated.
SD standard deviation, BCVA best-corrected visual acuity, CST central subfield thickness, CI confidence interval, NA not applicable.
S. Sivaprasad et al.
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patient’s better eye. The results for patients with BCVA 78 letters
or more are comparable to those of the Diabetic Retinopathy
Clinical Research Retina Network Protocol V study. Whilst no
control group was included in the DRAKO study design, the
reduced benefits observed in this subgroup support the conclu-
sion of Protocol V that a reasonable strategy for patients with high
VA may be observation without treatment unless VA worsens,
although there were few patients with >400 µm CST in Protocol V
(9% patients in the aflibercept group) [18]. Analysis of the DRAKO
year 2 results may provide further clarity on this clinically
important point.
These DRAKO observations are supported by several retro-
spective registry studies, which demonstrated the real-world
effectiveness of IVT-AFL for DMO treatment [19–21]. Notably,
fewer injections were recorded compared to clinical trials, and
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Fig. 2 Primary outcome results stratified by baseline measure and BCVA letter gain or loss proportion. A BCVA stratification, B BCVA letter
gain and loss proportion and C CST stratification, by sub-population. BCVA best-corrected visual acuity, CST central subfield thickness, PPW per
protocol window population, FAS full analysis set.
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baseline measures. In the UK-based, single-centre retrospective
cohort study conducted by Lukic et al. [21]., 99 eyes were
evaluated and a mean of 6.9 injections were administered.
The baseline VA (59.7 ETDRS letters) in this study was much
lower than DRAKO, so although the overall letter gain (9.9 letters)
was higher than that observed in DRAKO, in the 34% of eyes with
a baseline VA ≥69, the mean gain was 2.6 letters.
A similar ‘ceiling’ effect was observed in the CST subgroup
analysis. Baseline CST was stratified above or below 400 µm to
align with the NICE Technology Appraisal Guidance. The reduction
in CST for the baseline ≥400 µm subgroup was much greater than
for the <400 µm subgroup, but the mean CST at month 12 was
similar for both subgroups. The results suggest minimal difference
in terms of BCVA outcomes between the two subgroups, with a
marginally lower letter gain attained in the <400 µm subgroup,
although patient numbers were limited (n= 52).
The study has some limitations often inherent in non-
interventional studies such as, inconsistent treatment administra-
tion and non-defined functional eligibility metrics. However, the
prospective study design and wide range of sites contributing
enables treatment effects to be monitored across a diverse
population that aims to be representative of the UK as a whole. In
addition, the large number of anti-VEGF treatment-naive patients
enroled, and the high proportion of primary endpoint data
collected, strengthen the observations made during the study.
In conclusion, year one results indicate that IVT-AFL is an
effective treatment for DMO in real-world UK clinical practice,
maintaining or improving VA. Vision gains observed in DRAKO
were lower than in the pivotal clinical trials and several
observational studies [10, 14–16], perhaps reflecting better
baseline vision in UK clinical practice and/or a failure to adhere
to the SmPC for all patients. In addition, DRAKO demonstrated the
effectiveness of diabetic retinopathy screening in the UK, with
almost two-thirds of patients presenting with good baseline
vision.
The DRAKO data set contains a rich source of real-world ocular-,
treatment- and resource-related data that will mature further
upon completion of the study. It is anticipated that this will
provide a benchmark for better understanding of DMO IVT-AFL
outcomes and for shaping how DMO patient care pathways are
defined in the future.
SUMMARY
What was known before
● The effectiveness of intravitreal aflibercept (IVT-AFL) for
treatment of diabetic macular oedema (DMO) patients has
been demonstrated in several pivotal clinical trials (VIVID and
VISTA) and non-UK focused observational studies (APOLLON),
although such investigations primarily focused on patients
with baseline visual acuity of <73 letters.
● Retrospective registry-based studies of anti-vascular endothe-
lial growth factor (anti-VEGF) treatments have reported lower
injection frequency and functional gains than randomised
clinical trials.
● The scope for improvement of functional and anatomical
parameters in response to anti-VEGF treatment is closely
associated with baseline values.
What this study adds
● DRAKO is the first prospective non-interventional study to
evaluate IVT-AFL treatment of DMO patients across the UK,
demonstrating the effectiveness of this treatment to maintain
or improve patient outcomes across a diverse range of
local standard of care protocols, despite often observing
undertreatment compared with locally defined treatment
plans.
● DRAKO indicates the effectiveness of the diabetic retinopathy
screening programme in the UK where patients with DMO are
being identified and treated at a high level of VA, thereby
preserving patient vision.
REFERENCES
1. Written by Editor. Diabetes U. K. Cost of diabetes. 2019 https://www.diabetes.co.
uk/cost-of-diabetes.html. Accessed 19 Nov 2020.
2. International Diabetes Federation Diabetes Atlas ninth edition. 2019 https://
diabetesatlas.org/upload/resources/2019/IDF_Atlas_9th_Edition_2019.pdf.
Accessed 26 Nov 2020.
3. Fong DS, Aiello LP, Ferris FL 3rd, Klein R. Diabetic retinopathy. Diabetes Care.
2004;27:2540–53.
4. Musat O, Cernat C, Labib M, Gheorghe A, Toma O, Zamfir M, et al. Diabetic
macular edema. Rom J Ophthalmol. 2015;59:133–6.
5. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic
population. Ophthalmology. 1998;105:998–1003.
6. Stefánsson E, Bek T, Porta M, Larsen N, Kristinsson JK, Agardh E. Screening and
prevention of diabetic blindness. Acta Ophthalmol Scand. 2000;78:374–85.
7. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizu-
mab for diabetic macular edema: results from 2 phase III randomized trials: RISE
and RIDE. Ophthalmology. 2012;119:789–801.
8. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO,
et al. The RESTORE study: ranibizumab monotherapy or combined with laser
versus laser monotherapy for diabetic macular edema. Ophthalmology.
2011;118:615–25.
9. Do DV, Nguyen QD, Boyer D, Schmidt-Erfurth U, Brown DM, Vitti R, et al. One-year
outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular
edema. Ophthalmology. 2012;119:1658–65.
10. Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, et al.
Intravitreal aflibercept for diabetic macular edema. Ophthalmology.
2014;121:2247–54.
11. Eylea 40mg/ml solution of injection in a vial summary of product characteristics.
2012. https://www.medicines.org.uk/emc/product/2879/smpc#gref. Accessed 19
Nov 2020.
12. Brown DM, Schmidt-Erfurth U, Do DV, Holz FG, Boyer DS, Midena E, et al. Intra-
vitreal aflibercept for diabetic macular edema: 100-week results from the VISTA
and VIVID studies. Ophthalmology. 2015;122:2044–52.
13. Heier JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, et al.
Intravitreal aflibercept for diabetic macular edema: 148-week results from the
VISTA and VIVID studies. Ophthalmology. 2016;123:2376–85.
14. Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR,
Jampol LM, Aiello LP, Antoszyk AN, et al. Aflibercept, bevacizumab, or ranibizu-
mab for diabetic macular edema. N Engl J Med. 2015;372:1193–203.
15. Korobelnik JF, Daien V, Faure C, Tadayoni R, Giocanti-Auregan A, Dot C, et al. Real-
world outcomes following 12 months of intravitreal aflibercept monotherapy in
patients with diabetic macular edema in France: results from the APOLLON study.
Graefes Arch Clin Exp Ophthalmol. 2020;258:521–8.
16. Stefanickova J, Cunha-Vaz J, Ulbig M, Pearce I, Fernández-Vega Sanz A, Theo-
dossiadis P, et al. A noninterventional study to monitor patients with diabetic
macular oedema starting treatment with ranibizumab (POLARIS). Acta Ophthal-
mol. 2018;96:e942–9.
17. Ziemssen F, Schlottman PG, Lim JI, Agostini H, Lang GE, Bandello F. Initiation of
intravitreal aflibercept injection treatment in patients with diabetic macular
edema: a review of VIVID‑DME and VISTA‑DME data. Int J Retina Vitreous.
2016;2:16.
18. Baker CW, Glassman AR, Beaulieu WT, Antoszyk AN, Browning DJ, Chalam KV,
et al. Effect of initial management with aflibercept vs laser photocoagulation vs
observation on vision loss among patients with diabetic macular edema invol-
ving the center of the macula and good visual acuity: a randomized clinical trial.
JAMA. 2019;321:1880–94.
19. Ciulla TA, Pollack JS, Williams DF. Visual acuity outcomes and anti-VEGF therapy
intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes.
Br J Ophthalmol. 2021;105:216–21.
20. Bhandari S, Nguyen V, Fraser-Bell S, Mehta H, Viola F, Baudin F, et al. Ranibizumab
or aflibercept for diabetic macular edema: comparison of 1-Year outcomes from
the Fight Retinal Blindness! Registry. Ophthalmology. 2020;127:608–15.
S. Sivaprasad et al.
7
Eye
21. Lukic M, Williams G, Shalchi Z, Sim D, Patel PJ, Keane PA, et al. Intravitreal
aflibercept for diabetic macular oedema: Moorfields’ real-world 12-month visual
acuity and anatomical outcomes. Eur J Ophthalmol. 2020;30:557–62.
ACKNOWLEDGEMENTS
The DRAKO study was sponsored by Bayer Plc. Medical writing support was provided
by Andrea Parke of O4 Research and Apothecom Publications Ophthalmology, and
was funded by Bayer Plc. The DRAKO Study Group on behalf of Bayer Plc. would like
to thank the patients and investigators who have participated in the study.
AUTHOR CONTRIBUTIONS
SS, FG, SPK, AK, JT and PS were participating investigators in the study, played an
important role in interpreting the results and form part of the steering committee.
They reviewed, revised, provided feedback and approval of the manuscript, approve
the decision to submit for publication and agree to be accountable for all aspects of
the work. HM, AN, MS and JN participated in the study design, reviewed, revised,
provided feedback and approval of the manuscript, approve the decision to submit
the manuscript for publication and agree to be accountable for all aspects of
the work.
FUNDING
This study was sponsored by Bayer Plc, Reading. The sponsor participated in the
design of the study, conducting of the study, data collection, data management, data
analysis, data interpretation and preparation, review and approval of the manuscript.
COMPETING INTERESTS
SS received consultancy fees from Bayer, Allergan, Novartis Pharma AG, Roche,
Boehringer Ingelheim, Optos, Apellis, Oxurion, Biogen, Oculis and Heidelberg
Engineering. SS is Editor-in-Chief for the Journal Eye. Faruque Ghanchi has been a
consultant and speaker for Novartis, Bayer, Allergan, Alimera and Roche; and has
received travel grants from Bayer and Novartis. SPK received travel grants from Bayer,
research support from Bayer and Novartis Pharma AG, and participated in advisory
boards for Novartis Pharma AG and Polyphotopics. AK received travel support from
Novartis, Bayer, and Allergan, and speaker fees from Allergan and Bayer. JT
participated in advisory boards for Bayer and Novartis; received travel support from
Bayer; and received research grants from Bayer, Novartis and Roche. PS attended
advisory boards for Pfizer, Allergan, Boehringer, Roche and Bayer, and his department
has received educational, research, and audit grants from Allergan, Boehringer
Ingelheim, Novartis, and Bayer. HM is an employee of Bayer Plc. AN is an employee of
Bayer Plc. MS is an employee of O4 Research. JN is an employee of Bayer Plc.
ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s41433-021-01624-9.
Correspondence and requests for materials should be addressed to S.S.
Reprints and permission information is available at http://www.nature.com/
reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2021
S. Sivaprasad et al.
8
Eye
